blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2598508

EP2598508 - ISOXAZOLO-QUINAZOLINES AS MODULATORS OF PROTEIN KINASE ACTIVITY [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  26.02.2016
Database last updated on 16.07.2024
Most recent event   Tooltip12.10.2018Lapse of the patent in a contracting state
New state(s): AL		published on 14.11.2018  [2018/46]
Applicant(s)For all designated states
Nerviano Medical Sciences S.r.l.
Viale Pasteur, 10 P.O. Box 11
20014 Nerviano (MI) / IT
[2013/23]
Inventor(s)01 / CALDARELLI, Marina
Via Delle Forze Armate 260
I-20152 Milan / IT
02 / BERIA, Italo
Via S. Anna 16
I-20014 Nerviano / IT
03 / COLOMBO, Nicoletta
Via Passerella 5
I-22070 Bregnano / IT
04 / PIUTTI, Claudia
Via Papa Giovanni XXIII 21
I-20014 Nerviano / IT
05 / SALSA, Matteo
Via Libertà 186
I-28043 Bellinzago Novarese / IT
06 / TRAQUANDI, Gabriella
Via Cilea 106
I-20151 Milan / IT
 [2013/23]
Application number, filing date11734102.420.07.2011
WO2011EP62453
Priority number, dateEP2010017137530.07.2010         Original published format: EP 10171375
[2013/23]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2012013557
Date:02.02.2012
Language:EN
[2012/05]
Type: A1 Application with search report 
No.:EP2598508
Date:05.06.2013
Language:EN
The application published by WIPO in one of the EPO official languages on 02.02.2012 takes the place of the publication of the European patent application.
[2013/23]
Type: B1 Patent specification 
No.:EP2598508
Date:22.04.2015
Language:EN
[2015/17]
Search report(s)International search report - published on:EP02.02.2012
ClassificationIPC:C07D498/02, A61K31/517, A61P35/00
[2013/23]
CPC:
A61K31/519 (EP,US); A61K45/06 (US); A61N5/10 (US);
A61P35/00 (EP); A61P43/00 (EP); C07D498/02 (EP,US);
C07D498/04 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2013/23]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:ISOXAZOLO-CHINAZOLINE ALS MODULATOREN DER PROTEINKINASEAKTIVITÄT[2013/23]
English:ISOXAZOLO-QUINAZOLINES AS MODULATORS OF PROTEIN KINASE ACTIVITY[2013/23]
French:ISOXAZOLO-QUINAZOLINES EN TANT QUE MODULATEURS DE L'ACTIVITÉ PROTÉINE KINASE[2013/23]
Entry into regional phase13.02.2013National basic fee paid 
13.02.2013Designation fee(s) paid 
13.02.2013Examination fee paid 
Examination procedure13.02.2013Amendment by applicant (claims and/or description)
13.02.2013Examination requested  [2013/23]
31.10.2013Despatch of a communication from the examining division (Time limit: M04)
17.02.2014Reply to a communication from the examining division
10.03.2014Despatch of a communication from the examining division (Time limit: M04)
03.07.2014Reply to a communication from the examining division
11.09.2014Communication of intention to grant the patent
07.01.2015Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
06.02.2015Communication of intention to grant the patent
11.03.2015Fee for grant paid
11.03.2015Fee for publishing/printing paid
11.03.2015Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  31.10.2013
Opposition(s)25.01.2016No opposition filed within time limit [2016/13]
Fees paidRenewal fee
27.09.2013Renewal fee patent year 03
26.11.2014Renewal fee patent year 04
Penalty fee
Additional fee for renewal fee
31.07.201303   M06   Fee paid on   27.09.2013
31.07.201404   M06   Fee paid on   26.11.2014
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU20.07.2011
AL22.04.2015
AT22.04.2015
BE22.04.2015
BG22.04.2015
CY22.04.2015
CZ22.04.2015
DK22.04.2015
EE22.04.2015
FI22.04.2015
HR22.04.2015
LT22.04.2015
LV22.04.2015
MC22.04.2015
MK22.04.2015
MT22.04.2015
NL22.04.2015
PL22.04.2015
RO22.04.2015
RS22.04.2015
SE22.04.2015
SI22.04.2015
SK22.04.2015
SM22.04.2015
TR22.04.2015
LU20.07.2015
NO22.07.2015
GR23.07.2015
IS22.08.2015
PT24.08.2015
[2018/46]
Former [2018/31]HU20.07.2011
AT22.04.2015
BE22.04.2015
BG22.04.2015
CY22.04.2015
CZ22.04.2015
DK22.04.2015
EE22.04.2015
FI22.04.2015
HR22.04.2015
LT22.04.2015
LV22.04.2015
MC22.04.2015
MK22.04.2015
MT22.04.2015
NL22.04.2015
PL22.04.2015
RO22.04.2015
RS22.04.2015
SE22.04.2015
SI22.04.2015
SK22.04.2015
SM22.04.2015
TR22.04.2015
LU20.07.2015
NO22.07.2015
GR23.07.2015
IS22.08.2015
PT24.08.2015
Former [2017/39]HU20.07.2011
AT22.04.2015
BE22.04.2015
BG22.04.2015
CY22.04.2015
CZ22.04.2015
DK22.04.2015
EE22.04.2015
FI22.04.2015
HR22.04.2015
LT22.04.2015
LV22.04.2015
MC22.04.2015
MT22.04.2015
NL22.04.2015
PL22.04.2015
RO22.04.2015
RS22.04.2015
SE22.04.2015
SI22.04.2015
SK22.04.2015
SM22.04.2015
LU20.07.2015
NO22.07.2015
GR23.07.2015
IS22.08.2015
PT24.08.2015
Former [2017/22]AT22.04.2015
BE22.04.2015
CZ22.04.2015
DK22.04.2015
EE22.04.2015
FI22.04.2015
HR22.04.2015
LT22.04.2015
LV22.04.2015
MC22.04.2015
MT22.04.2015
NL22.04.2015
PL22.04.2015
RO22.04.2015
RS22.04.2015
SI22.04.2015
SK22.04.2015
LU20.07.2015
NO22.07.2015
GR23.07.2015
IS22.08.2015
PT24.08.2015
Former [2016/37]AT22.04.2015
BE22.04.2015
CZ22.04.2015
DK22.04.2015
EE22.04.2015
FI22.04.2015
HR22.04.2015
LT22.04.2015
LV22.04.2015
MC22.04.2015
NL22.04.2015
PL22.04.2015
RO22.04.2015
RS22.04.2015
SI22.04.2015
SK22.04.2015
LU20.07.2015
NO22.07.2015
GR23.07.2015
IS22.08.2015
PT24.08.2015
Former [2016/24]AT22.04.2015
CZ22.04.2015
DK22.04.2015
EE22.04.2015
FI22.04.2015
HR22.04.2015
LT22.04.2015
LV22.04.2015
MC22.04.2015
NL22.04.2015
PL22.04.2015
RO22.04.2015
RS22.04.2015
SI22.04.2015
SK22.04.2015
LU20.07.2015
NO22.07.2015
GR23.07.2015
IS22.08.2015
PT24.08.2015
Former [2016/15]AT22.04.2015
CZ22.04.2015
DK22.04.2015
EE22.04.2015
FI22.04.2015
HR22.04.2015
LT22.04.2015
LV22.04.2015
MC22.04.2015
NL22.04.2015
PL22.04.2015
RO22.04.2015
RS22.04.2015
SK22.04.2015
LU20.07.2015
NO22.07.2015
GR23.07.2015
IS22.08.2015
PT24.08.2015
Former [2016/13]AT22.04.2015
CZ22.04.2015
DK22.04.2015
EE22.04.2015
FI22.04.2015
HR22.04.2015
LT22.04.2015
LV22.04.2015
MC22.04.2015
NL22.04.2015
PL22.04.2015
RO22.04.2015
RS22.04.2015
SK22.04.2015
NO22.07.2015
GR23.07.2015
IS22.08.2015
PT24.08.2015
Former [2016/10]AT22.04.2015
CZ22.04.2015
DK22.04.2015
EE22.04.2015
FI22.04.2015
HR22.04.2015
LT22.04.2015
LV22.04.2015
NL22.04.2015
PL22.04.2015
RO22.04.2015
RS22.04.2015
SK22.04.2015
NO22.07.2015
GR23.07.2015
IS22.08.2015
PT24.08.2015
Former [2016/09]AT22.04.2015
DK22.04.2015
EE22.04.2015
FI22.04.2015
HR22.04.2015
LT22.04.2015
LV22.04.2015
NL22.04.2015
RS22.04.2015
NO22.07.2015
GR23.07.2015
IS22.08.2015
PT24.08.2015
Former [2016/07]AT22.04.2015
DK22.04.2015
FI22.04.2015
HR22.04.2015
LT22.04.2015
LV22.04.2015
NL22.04.2015
RS22.04.2015
NO22.07.2015
GR23.07.2015
IS22.08.2015
PT24.08.2015
Former [2015/51]AT22.04.2015
FI22.04.2015
HR22.04.2015
LT22.04.2015
LV22.04.2015
NL22.04.2015
RS22.04.2015
NO22.07.2015
GR23.07.2015
IS22.08.2015
PT24.08.2015
Former [2015/50]FI22.04.2015
HR22.04.2015
LT22.04.2015
LV22.04.2015
NL22.04.2015
RS22.04.2015
NO22.07.2015
GR23.07.2015
IS22.08.2015
PT24.08.2015
Former [2015/49]FI22.04.2015
HR22.04.2015
LT22.04.2015
LV22.04.2015
NL22.04.2015
RS22.04.2015
NO22.07.2015
GR23.07.2015
PT24.08.2015
Former [2015/42]NL22.04.2015
Cited inInternational search[A]WO2008074788  (NERVIANO MEDICAL SCIENCES SRL [IT], et al) [A] 1-23 * the whole document *;
 [A]WO2009156315  (NERVIANO MEDICAL SCIENCES SRL [IT], et al) [A] 1-23 * the whole document *;
 [AD]WO2004104007  (PHARMACIA ITALIA SPA [IT], et al) [AD] 1-23 * the whole document *;
 [A]WO03070706  (PHARMACIA CORP [US], et al) [A] 1-23 * the whole document *;
 [A]  - ITALO BERIA ET AL, "Identification of 4,5-Dihydro-1 H -pyrazolo[4,3- h ]quinazoline Derivatives as a New Class of Orally and Selective Polo-Like Kinase 1 Inhibitors", JOURNAL OF MEDICINAL CHEMISTRY, (20100513), vol. 53, no. 9, doi:10.1021/jm901713n, ISSN 0022-2623, pages 3532 - 3551, XP055011632 [A] 1-23 * the whole document *

DOI:   http://dx.doi.org/10.1021/jm901713n
 [A]  - GABRIELLA TRAQUANDI ET AL, "Identification of Potent Pyrazolo[4,3- h ]quinazoline-3-carboxamides as Multi-Cyclin-Dependent Kinase Inhibitors +", JOURNAL OF MEDICINAL CHEMISTRY, (20100311), vol. 53, no. 5, doi:10.1021/jm901710h, ISSN 0022-2623, pages 2171 - 2187, XP055011635 [A] 1-23 * the whole document *

DOI:   http://dx.doi.org/10.1021/jm901710h
 [A]  - MARIA GABRIELLA BRASCA ET AL, "Identification of N,1,4,4-Tetramethyl-8-{[4-(4-methylpiperazin-1-yl)p henyl]amino}-4,5-dihydro- 1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a Potent, Orally Available Cyclin Dependent Kinase Inhibitor", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, (20090715), vol. 52, no. 16, doi:10.1021/JM9006559, ISSN 0022-2623, pages 5152 - 5163, XP007909820 [A] 1-23 * the whole document *

DOI:   http://dx.doi.org/10.1021/jm9006559
 [A]  - ANGIOLINI M ET AL, "Structure-based optimization of potent PDK1 inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 20, no. 14, ISSN 0960-894X, (20100715), pages 4095 - 4099, (20100608), XP027103994 [A] 1-23 * the whole document *
by applicantWO2005037843
 WO2004104007
 WO2009156315
    - CURRENT OPINION IN CHEMICAL BIOLOGY, (1999), vol. 3, pages 459 - 465
    - CARCINOGENESIS, (2008), vol. 29, pages 1087 - 1091
    - MUSACCHIO A., SALMON D., NAT REV MOL CELL BIOL, (200705), vol. 8, no. 5, pages 379 - 93
    - STUCKE VM ET AL., EMBO J., (2002), vol. 21, no. 7, page 1723
    - WINEY M. ET AL., J. CELL BIOL, (1991), vol. 114, page 745
    - JONES, M.H. ET AL., CURR. BIOL., (2005), vol. 15, page 160
    - WEISS, WINEY, J., CELL. BIOL, (1996), vol. 132, page 111
    - JELLUMA, N. ET AL., CELL, (2008), vol. 132, page 233
    - JELLUMA N. ET AL., CELL, (2008), vol. 132, page 233
    - JELLUMA N. ET AL., PLOS ONE, (2008), vol. 3, no. 6, page E2415
    - SCHMIDT ET AL., EMBO REP, (2005), vol. 6, no. 9, page 866
    - YUAN B. ET AL., CLIN CANCER RES, (2006), vol. 12, no. 4, page 1121
    - CARTER SL ET AL., NAT GENET., (2006), vol. 38, no. 9, page 1043
    - BERTHEAU P. ET AL., PLOS MED, (2007), vol. 4, no. 3, page E90
    - DECARCER G. ET AL., CURR MED CHEM, (2007), vol. 14, no. 9, page 969
    - KOPS G. J. ET AL., NAT. REV CANCER, (2005), vol. 5, page 773
    - WEAVER ET AL., CANCER CELL, (2007), vol. 11, no. 1, page 25
    - RON D., NATURE, (1999), vol. 397, pages 271 - 2749
    - KOUMENIS C., THE EMBO JOURNAL, (2005), vol. 24, pages 3470 - 3481
    - F.W. STUDIER, "Protein production by auto-induction in high density shaking cultures", PROTEIN EXPRESSION AND PURIFICATION, (2005), vol. 41, doi:doi:10.1016/j.pep.2005.01.016, pages 207 - 234, XP027430000

DOI:   http://dx.doi.org/10.1016/j.pep.2005.01.016
    - M. COLOMBO, F. RICCARDI-SIRTORI, V. RIZZO, RAPID COMMUN. MASS SPECTROM., (2004), vol. 18, pages 511 - 517
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.